Trials / Completed
CompletedNCT01790828
Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A
Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha 'Registered' In Subjects With Hemophilia A
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 42 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is to describe the safety and efficacy of Xyntha® during the usual care setting.
Detailed description
non probability sample
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xyntha : coagulation factor IIIV (recombinant) | Xyntha will be administered according to physician's discretion. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-02-13
- Last updated
- 2015-08-17
- Results posted
- 2015-08-17
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01790828. Inclusion in this directory is not an endorsement.